Search Results
Results found for "Caldan Therapeutics"
- Dr. Graeme Milligan | Dr. GPCR Ecosystem
Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics
- In case you haven’t heard, registrations are open for the next 4-week course “Development of GPCR Ligands as Therapeutic Drugs,” with Dr. Terry Kenakin 👏 Spots are filling up fast, run and save yours, and enjoy a 25% discount with your Premium Membership 🚀 ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr | Dr. GPCR Ecosystem
you haven’t heard, registrations are open for the next 4-week course “Development of GPCR Ligands as Therapeutic ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs you haven’t heard, registrations are open for the next 4-week course “Development of GPCR Ligands as Therapeutic ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs
- An opportunity you won’t want to miss! ⚠️ The next 4-week course with Dr. Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register, save your spot, and spread the word. This event will only happen once this year! ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs for more information! #gpcr #drgpcr | Dr. GPCR Ecosystem
Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs
- 🔥 New Course Alert! “Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! Spots are filling up fast—Premium Members get 25% off! This advanced course is exclusively available in the Ecosystem, so don’t miss your chance to learn from the best. 🔹 Secure your spot now! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr #pharmacolgy #drugdiscovery #research | Dr. GPCR Ecosystem
“Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs “Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs
- Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer
Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and
- 🚀 Ready to dive into the world of GPCR drug development? Join Dr. Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! Get exclusive access to expert lectures, recordings, reading materials, and even a private call with Dr. Kenakin himself! Don’t miss this chance to level up your knowledge. 🔹 Spots are limited—save yours now! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr #pharmacolgy #drugdiscovery #research | Dr. GPCR Ecosystem
Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs
- ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery, you know that finding a promising candidate is just the start. A drug must also: ✅ Be absorbed into the body ✅ Reach the right target ✅ Stay long enough to be effective ✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery | Dr. GPCR Ecosystem
Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.
- 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. Terry Kenakin is hosting a 4-week course on GPCR drug development—and registration closes in 3 days! ⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance ✅ PK-PD modeling & therapeutic profiles ✅ Early safety assessments & toxicity risks 📌 Limited spots—sign up before March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharma #Biotech #Research | Dr. GPCR Ecosystem
⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance ✅ PK-PD modeling & therapeutic profiles 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. ⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance✅ PK-PD modeling & therapeutic profiles 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.
- 🚨 Exciting Opportunity for Professionals in Drug Development! 🚨 Register today for a one-of-a-kind online course at Dr. GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 ⏰ Time: Thursdays, 10:00 AM - 11:30 AM (EST) This advanced course is essential for anyone working in drug development and focuses on: The essentials of new drug development Key pharmacokinetic elements (absorption, distribution, clearance) Hepatic metabolism and the Cytochrome P450 system Drug safety and toxicology (including drug-drug interactions) And much more! Gain deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic molecules to life. 🚨 Only 25 spots available — register now! 💡 This is a great opportunity for both academia and industry professionals. Sessions will be live, and you’ll also have 1:1 discussion time with the instructor. Full PDFs of the slides will be available! 🔗 https://buff.ly/lVEcRUc #GPCR #DrugDevelopment #Pharmacokinetics #TherapeuticDrugs #OnlineCourse #DrGPCRUniversity #PharmaceuticalIndustry | Dr. GPCR Ecosystem
GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic 🔗 https://buff.ly/lVEcRUc #GPCR #DrugDevelopment #Pharmacokinetics #TherapeuticDrugs #OnlineCourse # GPCR University: "Development of GPCR Ligands as Therapeutic Drugs." 🗓 Dates: March 20 - April 10, 2025 deep insights into GPCR drug candidates and learn the critical assays and techniques required to bring therapeutic
- In case you haven’t heard, Dr. Terry Kenakin will soon start the course Principles of Pharmacology II - Advanced Methods for the Optimization of Candidate Selection 📖 The five-lecture series describes essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic opportunity. | Dr. GPCR Ecosystem
essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic
- Did you know? 🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! 🧬💡 These innovative compounds, “Photo-BQCisA” and “Photo-BQCtrAns,” offer subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic strategies targeting muscarinic receptors (M1-M5). 🔬✨ Learn more about this breakthrough in the Ecosystem! | Dr. GPCR Ecosystem
subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic
- Did you know that GPR20, a potential therapeutic target to treat gastrointestinal stromal tumours, performs high constitutive activity when coupling with Gi? Check out this paper to see how molecular dynamics simulation can be used to explore its constitutive activation mechanism. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/exploring-the-constitutive-activation-mechanism-of-the-class-a-orphan-gpr20 #gpcr #drgpcr | Dr. GPCR Ecosystem
Home → Flash News → Did you know that GPR20, a potential therapeutic target to treat gastrointestinal drgpcr Published on February 13, 2025 Category GPCR Weekly News Did you know that GPR20, a potential therapeutic
- Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand bias plays a key role in their success? This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock next-gen therapies. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr | Dr. GPCR Ecosystem
www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics
- Did you know that GPR180 helps regulate lipid metabolism and may play a role in preventing obesity? recent study shows that overexpression of GPR180 in adipose tissue improves lipid metabolism and protects against HFD-induced obesity, while its knockout worsens lipid accumulation. This finding highlights GPR180 as a potential therapeutic target for metabolic disorders! Catch up on this exciting research in the Ecosystem today! 🏆📖 You’ll need to register, but don’t worry—it’s free! ➡️https://www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/gpr180-reduces-adiposity-by-inhibiting-lipogenesis-and-fatty-acid-uptake-in-adipocytes #gpcr #drgpcr #metabolism #obesity | Dr. GPCR Ecosystem
This finding highlights GPR180 as a potential therapeutic target for metabolic disorders! This finding highlights GPR180 as a potential therapeutic target for metabolic disorders!
- 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you’ll learn: ✅ Drug Development Basics – Absorption, metabolism, PK principles ✅ Clearance & Distribution – Renal & hepatic clearance, key pharmacokinetics ✅ PK-PD Modeling – Predicting drug behavior, non-linear PK ✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling fast! Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery | Dr. GPCR Ecosystem
Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.
- We’re excited to announce our strategic partnership with Celtarys Research, a biotech company specializing in fluorescent ligand technologies and real-time, non-radioactive GPCR assays. This collaboration combines Dr. GPCR’s global platform with Celtarys’ innovative chemical biology tools, making it easier than ever for scientists to study ligand-receptor interactions, visualize binding, and accelerate drug discovery. We’re proud to welcome Celtarys to the Dr. GPCR ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics. ✳️Read the complete press release: https://www.ecosystem.drgpcr.com/post/dr-gpcr-and-celtarys-research-join-forces-to-expand-access-to-innovative-gpcr-tools #GPCR #DrGPCR #CeltarysResearch #DrugDiscoveryTools #FluorescentLigands #GPCRresearch #ScientificPartnership | Dr. GPCR Ecosystem
ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics ecosystem to support researchers worldwide and expand access to high-performance tools for GPCR-targeted therapeutics
- Dr. Nicolas Gilles | Dr. GPCR Ecosystem
He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic
- Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem
Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic
- Dr. Christel Menet | Dr. GPCR Ecosystem
I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr.
- Chris Langmead | Dr. GPCR Ecosystem
collaborative neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics , a biotech spin-out from the Neuromedicines Discovery Centre that is developing next-generation therapeutics Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology These successes enabled the US$400M sale of Heptares Therapeutics Ltd. to the Sosei Group Corporation
- Dr. Roger Sunahara | Dr. GPCR Ecosystem
bases for ligand binding and efficacy to help optimize the design and engineering of more efficacious therapeutics perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic
- Dr. Khaled Abdelrahman, Victoria Rasmussen and Madelyn Moore | Dr. GPCR Ecosystem
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic Maddi is currently a second year Ph.D. student in the Molecular Pharmacology and Therapeutics (MPaT)
- Dr. Juan José Fung | Dr. GPCR Ecosystem
Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Enjoying the Dr.
- A positive Allosteric Modulator of M1 Acetylcholine Receptors Improves Cognitive Deficits in Male and Female Alzheimer’s Mice
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics
- Dr. Khaled Abdelrahman | Dr. GPCR Ecosystem
He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics
- Dr. Samuel Hoare | Dr. GPCR Ecosystem
company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics
- Dr. Katarina Nemec | Dr. GPCR Ecosystem
I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically
- University - Landing Page | Dr. GPCR Ecosystem
created by scientists, for scientists—bringing the global GPCR community together to advance biology and therapeutics Explore 200+ expert talks that bring GPCR discoveries to life From structural biology to therapeutics players in GPCR pharmacology and learn how agonists and antagonists shape efficacy, signaling, and therapeutic orthosteric drugs and uncover the power of allosteric modulators and kinetic insights to unlock new therapeutic Take the Next Step You're building the future of GPCR therapeutics.
- Dr. Rosie Dawaliby | Dr. GPCR Ecosystem
In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases
- Dr. Stephane Angers | Dr. GPCR Ecosystem
He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics
